A randomized, controlled parallel-group trial has assessed 14 days' use of a new ankle support (Malleotrain, Bauerfeind, Aldershot, UK) in 220 patients (118 Malleotrain, 102 control group) with acute ankle injuries. Self-assessed pain levels were significantly lower in the group using Malleotrain at the end of the trial (P < 0.05), as were median times taken for reduction of symptom scores to 10% (P < 0.05) and total analgesic consumption during the trial (P < 0.05). Overall clinical assessment scores were significantly superior in the Malleotrain group (P < 0.02). Of those patients who received Malleotrain, 112 of 116 patients who commented (95% of all Malleotrain-treated patients) did so positively and only one patient stopped wearing the support during the trial. Malleotrain is acceptable to patients with acute ankle injuries and its use increases the rate of alleviation of symptoms. Its use should therefore be considered in the management of all such patients.
The treatment of major ankle trauma involving bony injury or major ligamentous damage requires specialist attention, involving surgery and/or total immobilization of the affected joint. Treatment of the more common minor ankle injuries relies mainly on analgesia and various forms of supportive bandages or strapping of the affected joint. Frequent intensive physiotherapy can hasten recovery, but the logistics and cost of such treatment preclude it from being made available to the majority of patients. However, such injuries can result in a significant period of impaired mobility (sometimes preventing the patient from working) and/or sporting activity. Any form of readily available treatment which hastens recovery without burdening physiotherapy or other paramedical resources would therefore be valuable.
Malleotrain (Bauerfeind, Aldershot, UK) is a sophisticated elasticated ankle support with specially shaped silicone rubber inserts ( Figure 1 ). These inserts not only maximize the support offered but also achieve constant massaging of the affected soft tissues, thereby emulating some of the techniques of physiotherapy which could be utilized. This aspect of treatment with Malleotrain has been described as 'active therapy'.
It has been suggested that the high quality of ankle support, together with the feature of ' 
Assessments
The primary assessments of treatment efficacy were on the basis of daily self-assessment by patients, using diary cards. Pain self-assessment utilized 7-cm horizontal Visual Analogue Scales (VAS), labelled 'none' at one end and 'worst imaginable' at the other. These scales were applied separately to pain in three situationsat rest, during activities and during the night.
Limitation of activity was also assessed on a 7-cm VAS, labelled 'no limitation' at one end and 'no activity possible' at the other.
Patients also recorded whether they were able to work and the number of doses of analgesia taken during the day.
At the end of the trial, patients assessed their improvement on a 6-point scale (0, much worse; 1, slightly worse; 2, no change; 3, slightly better; 4, much better; 5, cured).
At the end of the trial, patients were questioned regarding their current activity/work status. Those in the active treatment group were also questioned regarding the comfort and ease of use of Malleotrain.
Statistical methods
The significance of within-patient changes within groups was assessed using Wilcoxon's signed rank tests, Kolmogorov-Smirnov tests or paired t-tests. The two groups were compared using Mann-Whitney, Kolmogorov-Smirnov, x2 and unpaired t-tests, as appropriate, applied to the withingroup changes during treatment.
In relation to the diary VAS data, two overall indices of symptoms were derived: areas under the response-time curves (trapezium method) and the time for each of the VAS scores to fall to 10% or less.
The number of patients in the trial was the number estimated to be required to achieve a power (1- Malleotrain. The median total number of doses of analgesia taken during the 14-day trial period was 11.0 in the Malleotrain group, compared with 25.6 in the control group (P < 0.05; Mann-Whitney U test).
Speed of response A fall of VAS to 10% occurred more rapidly in the group on Malleotrain for all four assessments, significantly so in the case of pain at night and at rest; Mann-Whitney U test. The improvement with Malleotrain was in the range 2-3 days (Table 2) However, despite the inevitable problems with a trial of this sort, the results demonstrate consistent differences between treatment groups. Malleotrain resulted in greater and more rapid improvement, significantly so in relation to the majority of assessment criteria. Overall assessments were significantly in favour of Malleotrain. Those patients who received the treatment nearly all commented favourably upon it -in only one case was its use discontinued.
